Investors of Telix Pharmaceuticals Are Advised to Reach Out to The Gross Law Firm by January 2026

Important Notice for Shareholders of Telix Pharmaceuticals Ltd.

In an announcement made by The Gross Law Firm on December 1, 2025, shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) are urged to contact the firm due to significant developments concerning their rights. If you purchased shares of TLX within the class period ranging from February 21, 2025, to August 28, 2025, you may have legal grounds to act.

Allegations Against Telix Pharmaceuticals

The complaint accuses the defendants of making materially false or misleading statements that significantly impacted the company’s stock performance. Specifically, it highlights that:
1. The progress Telix had claimed regarding its prostate cancer therapeutic candidates was exaggerated.
2. The integrity and reliability of Telix's supply chain and partners were overstated.
3. Overall, statements made about the company’s operations and future prospects were misleading and lacked a factual basis during this crucial period.

The Deadline for Action

Shareholders are reminded that to pursue potential claims or to be appointed as lead plaintiffs in a class action, the deadline is January 9, 2026. It is essential for investors to register without delay to secure their chance at recovery.

Next Steps for Shareholders

By registering with The Gross Law Firm, shareholders will be integrated into a portfolio monitoring system, which will provide ongoing updates throughout the duration of the case. There are no costs or obligations incurred by participants for this registration and case involvement.

Why Choose The Gross Law Firm?

The Gross Law Firm is renowned nationally for its dedication to protecting the rights of investors who have suffered losses due to misleading corporate practices. The firm is committed to ensuring responsible and ethical behavior from corporations and seeks restitution for investors when misinformation leads to unjustified stock value inflation.

How to Get in Touch

For those interested in discussing their situation or learning more about the proceedings, The Gross Law Firm offers direct contact options:

- Address: 15 West 38th Street, 12th floor, New York, NY, 10018
- Email: [email protected]
- Phone: (646) 453-8903

Investors are encouraged to act swiftly, as the window for potential recovery is limited. By taking these proactive steps, shareholders can better safeguard their interests amidst evolving corporate challenges at Telix Pharmaceuticals.